Adoptive transfer of immunity against hepatitis B surface antigen (HBsAg) has been documented in mice and humans. In the present study, we report long-term follow-up of antibodies to HBsAg in humans who received allogeneic bone marrow transplantation (BMT) from donors immunized with HBsAg. BM donors were immunized with recombinant HBsAg. BM or PB cells were transplanted to HLA matched recipients. Recipients were followed for anti-HBs seroconversion. Control groups included non-immunized or rHBsAg immunized healthy adults as well as individuals that had had hepatitis B and recovered spontaneously. PBLs were stimulated in vitro with rHBsAg and stimulation was expressed as stimulation index. Adoptive transfer of immunity to HBsAg was initially documented in 12 recipients of BM from anti-HBc+/anti-HBs+ donors. An almost 4 year follow-up showed detectable protective anti-HBs levels (Ͼ10 mIU/ml) in 50% of patients. Immunity to HBV was also documented in 22/35 BMT recipients (62%), who received their bone marrow from actively immunized donors. In 7/9 of these BMT recipients, anti-HBs antibodies levels were documented 25 months following BMT. In 6/8 (75%) of patients who received only PBLs from HBV immune donors, adoptive transfer of immunity to HBV, and seroconversion to HBsAg+, were documented within 2 months of i.v. injection. Evidence for specific cellular immune response with increased SIs was documented for healthy vaccinees, and BMT recipients, and in none of the healthy non-vaccinated controls. These results suggest that adoptive transfer of immunity to HBV is a useful method for providing long-lasting protection for BM recipients. Bone Marrow Transplantation (2000) 26, 633-638.
Hepatitis B virus (HBV) infection is a major cause for chronic liver disease worldwide. 1, 2 Resolution of acute HBV infection is dependent on an intact cytolytic T cell response against nucleocapsid antigens while protection against future HBV challenge requires the presence of an intact immune memory against envelope protein(s). 3, 4 It is currently believed that defective T and B cell responses to the viral surface and/or nucleocapsid antigens may be associated with inefficient virus clearance. [3] [4] [5] HBV infection is a known factor in liver dysfunction in patients undergoing bone marrow transplantation (BMT). 6, 7 Such patients are pancytopenic for several weeks, and immunocompromised for many months, following BMT, as a result of their disease, conventional anti-cancer treatment, the myeloablative chemo-radiotherapy used for conditioning, and the long-term immunotherapy which they receive. [8] [9] [10] Furthermore, BMT recipients remain severely immunosuppressed because of prophylactic treatment against graft-versus-host disease (GVHD), which by itself is associated with impaired immunological function. 8 HBV infection, whether overt or latent, has been shown to be augmented or reactivated following administration or withdrawal of immune suppression, leading occasionally to fulminant hepatitis. 3, 6 Attempts at active immunization against HBV in the immediate pre-and post-BMT period were unsuccessful, probably due to inefficient T cell-dependent B cell responses, which may last for about a year following BMT. 10, 11 Failure of effective immunization in BMT recipients was also reported for other vaccines, such as Pseudomonas, rubella, mumps, and measles. 10, 12 Over the last 10 years, adoptive transfer of humoral and cell-mediated immunity to BMT recipients through vaccination of bone marrow donors has been suggested as a means of protecting immunocompromised patients against bacterial and viral infections. [13] [14] [15] [16] Such a strategy has been shown to be particularly effective in humans using vaccines against tetanus, diphtheria, varicella, Pseudomonas, and hepatitis B.
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The use of specific adoptive immunotherapy to restore immune responses to viruses and tumors is especially valuable in the BMT setting because of the immunedeficiency induced by the treatment regimen and the time required for immune reconstitution. 17 Several studies have recently provided strong supportive evidence for the use of adoptive transfer of immunity towards CMV in humans. 22, 23 BMT recipients who received anti-CMV immunized CD8 + CTL in a clinical trial had no evidence of viremia, suggesting reconstitution of the T cell immunity by the adoptive T cell therapy that prevents CMV reactivation. 19, 22 Similarly, recent studies have shown that adoptive transfer of immunity towards EBV may prevent EBV infection, may be used for pre-existing disease, and may have long-term effects on preventing EBV-associated complications such as lymphoproliferative disorders. [24] [25] [26] [27] [28] [29] [30] Others and ourselves have recently shown in mice and humans that immunity to HBsAg can be transferred from anti-HBs-positive bone marrow and peripheral blood donors to anti-HBs negative recipients through bone marrow containing stem cell transplantation. [31] [32] [33] [34] [35] [36] The follow-up in humans of anti-HBV immune responses was restricted to the humoral response, relatively short, and did not exceed 1 year in the majority of patients.
We now report the follow-up of some cellular and humoral immune responses against the small envelope HBV protein over a period of more than 3 years in those patients who are long-term survivors of BMT.
Materials and methods

Patients
Retrospective analysis: Twelve pairs of BMT recipients were originally identified among 178 pairs of BMT donors and recipients in the early 1990s in whom all bone marrow donors were anti-HBc+/anti-HBs+ (as evidence for previous HBV infection and resolution), and all recipients were anti-HBc, anti-HBs and HBsAg negative prior to BMT. Eight donors were males, four were females, with a mean age of 23 ± 7.8 years. Sera for anti-HBs and antiHBc determination post BMT was available from random dates, not designed by protocol. All patients were followed for anti-HBs levels with a mean follow-up of 55.2 months (range 12-74. 4 
months).
Prospective study: Thirty-six BMT recipients, negative for anti-HBc, anti-HBs and HBsAg, underwent allogeneic T cell-depleted BMT from donors actively vaccinated against HBV using a recombinant HBsAg vaccine prior to bone marrow donation. All donors and recipients were fully matched for HLA-A, B, DR, with unreactive lymphocyte culture. Eight had non-Hodgkin's lymphoma (NHL), eight had chronic myeloid leukemia (CML), seven had lymphoblastic leukemia, six had acute non-lymphoblastic leukemia (ANLL), two had aplastic anemia, three had myelodysplastic syndrome (MDS), one had thalassemia, and one had Fanconi's anemia. Patients with myelodysplastic syndrome, acute leukemia, and acute non-lymphocytic leukemia were conditioned by fractionated total body irradiation (TBI 1200 cGy in six fractions), followed by etoposide (1500 mg/m No anti-GVHD prophylactic therapy was administered to patients with T cell-depleted grafts while patients transplanted with unmanipulated marrow received cyclosporin A with or without methotrexate as anti-GVHD prophylaxis. The study was approved by the Institutional Review Board and the Israeli Ministry of Health.
Immunization against hepatitis B
Active immunization using either Engerix B (Smith Klein Beecham, Brussels, Belgium, 20 g/ml) or HB-Vax II (Merck & Co, Whitehouse Station, NJ, USA, 10 g/ml), was administered into the deltoid muscle to anti-HBc negative, anti-HBs negative, HBsAg negative BMT donors. BMT procedures were usually performed at short notice on a semi-emergency basis as a result of clinical deterioration. Therefore, bone marrow donors were immunized only once with a single dose of 10 or 20 g HBsAg within 11-30 days before bone marrow donation. All BMT recipients received 10 or 20 g booster injections i.m. into the deltoid muscle at 30, 60 and 150 days following BMT. Blood samples from BMT recipients were drawn periodically, and separated serum stored at −20°C. All BMT recipients were followed for a mean period of 25 ± 4.3 months (range 6-39) for anti-HBs serum levels.
Eight patients underwent autologous BMT followed by allogeneic HLA-matched peripheral blood lymphocytes (PBL), as adoptive immunotherapy in an attempt to reduce relapse rates post BMT. Three were transplanted for acute lymphocytic leukemia, three for acute myelocytic leukemia, and two for chronic myelocytic leukemia, followed by i.v. PBL administration post BMT. All eight donors were tested for absence of previous or present HBV infection by serological tests, for anti-HBc and anti-HBs. One day after harvesting of bone marrow cells, donors were immunized twice with recombinant HBsAg (on day 1 and day 30 after BMT donation). Seroconversion was ascertained by determination of anti-HBs. All BMT recipients were examined for anti-HBs levels every 7 days post PBL donation, and all received one booster vaccination with the recombinant HBsAg vaccine within 40-45 days after injection of PBL. Long-term follow up was available in three of the anti-HBs positive recipients for 18 ± 3.4 months (range 9-23).
Follow-up of humoral immune responses to hepatitis B
Anti-HBc, anti-HBcIgM, HBsAg and anti-HBs in serum were determined by radioimmunoassays or EIA assays (Abbott Laboratories, North Chicago, IL, USA). A World Health Organization reference serum was used for quantitative analysis of anti-HBs as described. 37 
Determination of cellular immune response towards HBsAg
Peripheral blood lymphocytes obtained from BMT recipients (n = 5), from healthy adults immunized with rHBsAg (n = 14), from anti-HBc positive/anti-HBs positive healthy adults (n = 4), and from non-vaccinated healthy controls (n = 6), were stimulated for 7 days with rHBsAg and pulsed with 3 H-thymidine as described. 38 Specific stimulation as proof of cellular immune response was expressed as stimulation index (SI).
Statistics
Student's t-test was used for all statistical calculations.
Results
Adoptive transfer of immunity against HBV from HBV immune donors who have had HBV and recovered
Adoptive transfer of immunity against HBV from antiHBc/anti-HBs positive HBV immune donors who had had HBV and recovered spontaneously, occurred in all 12 naive HBV recipients tested retrospectively. Mean anti-HBs level prior to BMT in 12 BMT donors was 3834 ± 176 mIU/ml and all had normal alanine amino transferase levels. All BMT recipients developed protective anti-HBs levels above 10 mIU/ml with a mean value of 155 ± 33 mIU/ml (range 35-182 mIU/ml). During a follow-up of up to 6 years, 4/12 patients died and two were lost to follow-up. Of the remaining six patients, three had evidence of anti-HBs levels up to 112 ± 28 mIU/ml (range 63-189 mIU/ml) for a mean period of 4.6 years following BMT (range 1-6.2 years; Figure 1 ).
Adoptive transfer of immunity against HBV from actively immunized bone marrow donors -prospective follow-up
Forty-five BMT donors were actively immunized against HBV between days −30 and −11 before BMT. Despite the short time available between primary immunization and BMT, 35/45 donors seroconverted to anti-HBs by the day of bone marrow donation after receiving one to two doses of the HBV vaccine with a mean anti-HBs level of 100 ± 25 mIU/ml (range 18-236 mIU/ml). Seroconversion to anti-HBs+ occurred in 22/35 BMT recipients (63%) whose BM donors were immunized against HBV. Seroconversion was documented as early as day 9 and up to day 52 following BMT. Mean anti-HBs level on day 30 following BMT was 59 ± 7 mIU/ml (range 27-110 mIU/ml). Mean anti-HBs level after two booster injections observed on day 90 post BMT was 53 ± 8 mIU/ml (range 22-102 mIU/ml). The response to booster immunization varied. The most frequent pattern of adoptive transfer of immunity to HBV was characterized by seroconversion to anti-HBs soon after BMT with stabilization of antibody levels above the protective range of 10 mIU/ml, but with a sluggish response to repeated booster injections (four patients). Three patients developed a secondary immune response against HBsAg with an almost three-fold rise in anti-HBs titers within 30 days following booster immunization. The third pattern of response occurred in patients, when relapse of their disease resulted in loss of initial seroconversion with disappearance of detectable anti-HBs 90 to 200 days following BMT. Of the 22 patients that seroconverted, four were lost to follow-up and nine died. Follow-up continued on the nine patients for a mean of 25 ± 4.3 months. In 7/9 cases, antiHBs levels were above the conventional protective levels against HBV infection with a mean of 102 ± 13 mIU/ml (range 22-183; Figure 2 ). No significant adverse events were observed following immunization against HBV in both BMT donors and recipients.
Induction of immunity to HBsAg through adoptive transfer of peripheral blood lymphocytes obtained from immunized donors
Adoptive transfer of immunity towards HBsAg was documented in 6/8 patients following transplantation of PBLs from donors immunized against HBV. In four patients in whom seroconversion to anti-HBs was documented within 27-45 days following PBL transfer, there was a marked secondary immune response to booster immunization with rHBsAg. Two patients seroconverted 18 and 25 days following PBL administration but lost their anti-HBs marker with relapse of their leukemia. Long-term follow-up was available on three of the anti-HBs positive patients for 18 ± 3.4 months (range 9-23). In these three cases anti-HBs Bone Marrow Transplantation Time post BMT (months)
Anti-HBs (mIU/ml) 3 Figure 3 Long-term follow-up of anti-HBs serum levels following adoptive transfer of immunized PBL. In six out of eight patients adoptive transfer of immunity towards HBV occurred following transplantation of immunized PBLs. In four patients high anti-HBs titers appeared 27-45 days following PBL donation and showed marked secondary immune response after booster administration. Long-term follow-up was available on three of the positive patients for 18+ 3.4 months (range 9-23). In all three cases anti-HBs levels remained above the protective levels with a mean of 89 + 13 mIU/ml (range 33-112 mIU/ml). levels remained above the protective levels with a mean of 89 ± 13 mIU/ml (range 33-112 mIU/ml; Figure 3 ).
Cellular immune response to HBsAg
Evidence for a specific cellular immune response towards HBsAg (SI Ͼ3), as manifested by a high stimulation index ranging between 3 and 63 was documented in 4/5 BMT recipients, 6/14 healthy vaccinees, and in none of the healthy non-vaccinated controls. Following an HBsAg booster, all BMT recipients as well as healthy control vaccinees developed a specific response against HBsAg (Table 1) .
Discussion
The present report confirms and extends previous observations of our group that immunity against hepatitis B envelope and nucleocapsid proteins can be adoptively transferred through bone marrow transplantation as well as through cell therapy using peripheral blood lymphocytes.
In a follow-up study of these patients, we now show that immune memory to HBsAg may be maintained for up to almost 4 years in initially immunosuppressed BMT and PBL recipients transplanted with HBV immune lymphocytes. Transplantation of HBV immune cells may also be useful in patients with persistent HBV infection in whom 31, 32 Clearance of peripheral markers of HBV infection has been observed repeatedly in BMT patients who received their bone marrow from HBV immune donors. However, it is not yet known whether such clearance, as determined by negative HBV-DNA or even HBV-DNA by PCR assays, represents complete resolution of persistent HBV infection or only a decrease in viral load and activity. Furthermore, the relative role of individual cellular and humoral immune responses to HBsAg and/or to HBcAg in resolution of HBV infection following adoptive transfer through BMT or PBLs remains to be explored. This will eventually require evaluation of adoptive transfer of immunity in BMT recipients who received their BM from donors immunized with rHBsAg (including pre-s1/pre-s2) and or HBcAg.
Antigen-specific adoptive transfer of immunity through administration of T cells reactive with target proteins has been documented in a number of models and clinical situations. [16] [17] [18] [19] [20] [21] [22] [23] [24] For example, murine CMV infection that exhibits a similar genomic organization to human CMV has been utilized in a model system for proof of concept. 19, 23 Infection with this virus leads to persistent latent infection in healthy hosts and may reactivate and disseminate in immunodeficient hosts. Mice infected with murine CMV have been used to evaluate the nature of the immune response and the disease. Adoptive transfer of mouse CMV-specific CD8 cytotoxic T lymphocytes was shown to protect irradiated mice with previously latent mouse CMV infection from developing fatal CMV disease. 19, 23 Elucidation of the immunobiology of CMV infection provided support for use of adoptive transfer of immunotherapy towards viral infections. Several studies in animal models and humans have supported the role of T cells in the anti-EBV immunity using adoptive cell therapy. [24] [25] [26] [27] Moreover, recent studies have shown that EBV-associated lymphoproliferative disorders develop as a result of an inadequate CTL response to B cells expressing EBV latent proteins. Thus EBV-specific T cell therapy was pursued as a mean for preventing or treating this disease. [23] [24] [25] [26] [27] Advances over the past 5 years have provided the framework for the use of the technique in humans. Methods for isolating and expanding antigen-specific T cells have developed enabling effective transfer of antigen-specific T cells. [16] [17] [18] Correlative studies in BMT recipients of viral immunity and the development of CMV disease have provided further evidence for a critical role of CD8 + T cells in providing protection in immunosuppressed patients. This method carries the advantage of enabling effective protection of immunosuppressed patients against various infectious agents such as CMV and EBV in BMT recipients. 16, 17 The use of adoptive transfer of immunity against HBV is intended to bypass immunological non-responsiveness to Bone Marrow Transplantation persistent HBV infection or to conventional vaccination. 21, [32] [33] [34] Phenotyping of the immune cells which take part in this maneuver is still under investigation. [39] [40] [41] The results of the present study show that recipients of HBV immune BMT maintain a cellular immune response of proliferative CD4
+ cells against HBsAg for several years after BMT even in the absence of detectable anti-HBs.
Further studies are required to explore the utilization of adoptive cell therapy for clearance of persistent HBV infection and possibly also elimination of tumor cells, which express specific viral antigens. Potential applications for this strategy include, bypassing of non-responsiveness to conventional vaccination against HBV or against other infectious agents in immunosuppressed individuals at risk, protection of liver transplant recipients against re-infection of the graft with HBV, and possibly also treatment of persistent HBV infection. Although the risks involved with this procedure are not fully elucidated, the clinical application may be promising.
